Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (LSE:0R1F) — Drug Manufacturers - General. Število borz, na katerih se trgujejo delnice družbe: 6. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O Podjetju
- Spletna Stran
- bms.com
- Odnosi z Vlagatelji
- bms.com/investors.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Sedež
- PRINCETON, United States
- Izvršni Direktor
- Christopher S. Boerner
- Zaposleni
- 32 500
- Ustanovljena
- 1989
- Delnice v Obtoku
- 2.04 mrd. na dan 2026-07-22
- Prosto Prenosljive Delnice
- 2.04 mrd.
- Tržna Kapitalizacija
- 128.41 mrd. USD
- Notranje Osebe
- 0.1%
- Institucionalni Vlagatelji
- 84.87%
- Panoga (SIC)
- Pharmaceutical Preparations
- Pravna Oblika
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Delež Izplačila
- 54.9%
- FCF
- 11.4 mrd. USD
- Izplačilo / FCF
- 45%
- Dolg
- 43.9 mrd. USD3.1 let FCF
- Dividendni Staž
- 54 let
- Dobički, FCF in izplačane dividende — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
- NAV
Opis
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Borze in Oznake
| Borza | Oznaka | Valuta | Cena | Vrsta |
|---|---|---|---|---|
| US USA Stocks | BMY glavna | USD | 59.28 +4.61% | navadne delnice |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | navadne delnice |
| MI Borsa Italiana (Milan) | 1BMY dodatna | EUR | 54.3 -1.08% | navadne delnice |
| MX Mexican Stock Exchange | BMY dodatna | MXN | 1 130 +7.93% | navadne delnice |
| VI Vienna Stock Exchange | BMYS dodatna | EUR | 52.98 +0.34% | navadne delnice |
| XETRA Xetra | BRM dodatna | EUR | 53.04 +0.89% | navadne delnice |
Dividende
Bristol-Myers Squibb Company (BMY) izplačuje dividende četrtletno. Na leto (12 mesecev do in vključno z najnovejšim napovedanim plačilom): 2.52 USD na delnico (plačila: 4). To je približno 4.25% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 01.01.2027. Leta neprekinjenih dividend: 54.
| Ex-Datum | Izplačilo | Znesek | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-10-02 | 2026-11-02 | 0.6300 USD | 1.0/4.1 % | četrtletno | US:BMY |
| 2026-07-02 | 2026-08-03 | 0.6300 USD | 1.1/4.4 % | četrtletno | US:BMY |
| 2026-04-02 | 2026-05-01 | 0.6300 USD | 1.0/4.0 % | četrtletno | US:BMY |
| 2026-01-02 | 2026-02-02 | 0.6300 USD | 1.2/4.6 % | četrtletno | US:BMY |
| 2025-10-03 | 2025-11-03 | 0.6200 USD | 1.4/5.4 % | četrtletno | US:BMY |
| 2025-07-03 | 2025-08-01 | 0.6200 USD | 1.3/5.2 % | četrtletno | US:BMY |
| 2025-04-04 | 2025-05-01 | 0.6200 USD | 1.1/4.2 % | četrtletno | US:BMY |
| 2025-01-03 | 2025-02-03 | 0.6200 USD | 1.1/4.3 % | četrtletno | US:BMY |
| 2024-10-04 | 2024-11-01 | 0.6000 USD | 1.0/4.0 % | četrtletno | US:BMY |
| 2024-07-05 | 2024-08-01 | 0.6000 USD | 1.0/4.0 % | četrtletno | US:BMY |
| 2024-04-04 | 2024-05-01 | 0.6000 USD | 1.0/3.9 % | četrtletno | US:BMY |
| 2024-01-04 | 2024-02-01 | 0.6000 USD | 1.0/3.9 % | četrtletno | US:BMY |
| 2023-10-05 | 2023-11-01 | 0.5700 USD | 1.0/3.8 % | četrtletno | US:BMY |
| 2023-07-06 | 2023-08-01 | 0.5700 USD | 1.0/3.8 % | četrtletno | US:BMY |
| 2023-04-06 | 2023-05-01 | 0.5700 USD | 1.0/3.7 % | četrtletno | US:BMY |
| 2023-01-05 | 2023-02-01 | 0.5700 USD | 1.0/3.7 % | četrtletno | US:BMY |
| 2022-10-06 | 2022-11-01 | 0.5400 USD | 0.9/3.6 % | četrtletno | US:BMY |
| 2022-06-30 | 2022-08-01 | 0.5400 USD | 0.9/2.7 % | četrtletno | US:BMY |
| 2022-03-31 | 2022-05-02 | 0.5400 USD | 0.9/1.8 % | četrtletno | US:BMY |
| 2022-01-06 | 2022-02-01 | 0.5400 USD | 0.9/0.9 % | četrtletno | US:BMY |
Največji Imetniki
| Imetnik | Delež | Delnice | Datum Poročila |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mio. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mio. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mio. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mio. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mio. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mio. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mio. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mio. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mio. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mio. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mio. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
